Universal Biosensors Inc. (UBI) has signed a non-exclusive licence agreement with Australian company, SpeeDx Pty Ltd., for access to its proprietary MNAzyme technology. The SpeeDx technology is a sensitive and highly selective method for detecting sequences of DNA or RNA. The agreement allows UBI to utilize SpeeDx’s proprietary technology in combination with UBI's diagnostic biosensor to access the rapidly growing molecular diagnostics market. UBI will seek to develop a molecular diagnostic platform that can deliver rapid, low cost results at the point-of-care.

UBI CEO, Paul Wright said, “I am very pleased to announce this licence agreement between two Australian companies at the forefront of their respective fields. The incorporation of SpeeDx’s technology with the UBI strip technology is a very exciting prospect. Having further validated the breadth of our technology with our recent deal with Siemens, we are now well placed to pursue further opportunities in this large emerging market. Performing molecular diagnostics at the point-of-care would have significant advantages for patients and UBI is looking forward to addressing this unmet need by developing low cost, rapid tests."

-Richard Park